There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zogenix (ZGNX) and SAGE Therapeutics (SAGE) with bullish sentiments.
Zogenix (ZGNX)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix today and set a price target of $55.00. The company’s shares closed last Thursday at $22.08, close to its 52-week low of $16.65.
According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -9.6% and a 32.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Nektar Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zogenix with a $48.25 average price target.
See today’s analyst top recommended stocks >>
SAGE Therapeutics (SAGE)
Mizuho Securities analyst Vamil Divan upgraded SAGE Therapeutics to Buy today and set a price target of $81.00. The company’s shares closed last Thursday at $69.86.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.1% and a 46.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and Revance Therapeutics.
Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $85.60, a 25.7% upside from current levels. In a report issued on November 27, Raymond James also assigned a Buy rating to the stock with a $88.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
